Molecular Formula | C24H30Cl2N2O3 |
Molar Mass | 465.41 |
Melting Point | 212-213° |
Solubility | methanol: >10mg/mL |
Appearance | solid |
Color | white |
Storage Condition | Sealed in dry,Room Temperature |
In vitro study | Besides being an alpha 1-adrenoceptor antagonist, Naftopidil diHCl also has 5-HT1A Agonistic properties. Naftopidil has a growth inhibitory effect in androgen sensitive and insensitive human prostate cancer cell lines. Naftopidil inhibited the growth of androgen-sensitive LNCaP cells and androgen-insensitive PC-3 cells with an IC50 of 22.2 μm and 33.2 μm, respectively. The inhibition of cell growth by Naftopidil is due to the arrest of the G1 cell cycle. In Naftopidil-treated cells, p27 Naftopidil significantly attenuated enuresis against collagen-induced Ca Naftopidil compared to tamsulosin. In PCa cells and prscs, Naftopidil induces G(1) cell arrest. In Naftopidil treated prscs, total interleukin-6 was significantly reduced with increased inhibition of cell proliferation. |
In vivo study | Oral administration of Naftopidil to nude mice inhibited tumor growth by PC-3 compared to the vehicle control group. Naftopidil increases bladder volume and relaxes micturition muscles by inhibiting afferent nerve activity. Naftopidil (0.1 μg-30 μg) temporarily abolished isovolumic rhythmic bladder contraction. The amplitude of bladder contraction was reduced by intrathecal naftopidil (3 μg to 30 μg). In an anesthetized dog model, Naftopidil selectively inhibited the phenylephrine-induced increase in prostate pressure compared to mean blood pressure. |
WGK Germany | 3 |
RTECS | TL9336500 |